Clinical Trial Update: Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism [Phase 3]

View source ↗

Summary

A Phase 3 trial of CTAP101 extended-release capsules in children with secondary hyperparathyroidism was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism
• Vitamin Deficiency

Drugs mentioned

• CTAP101 Extended-release Capsules

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Chronic Kidney Disease stage3, Chronic Kidney Disease stage4 | Phase 3 | Status: TERMINATED | Results posted: 2025-07-25